Cargando…

Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma

SIMPLE SUMMARY: Esophageal adenocarcinoma (EAC) is a cancer with very poor survival outcomes. Patients are treated with pre-operative chemotherapy or chemoradiotherapy before surgery. However, four out of every five patients do not respond to pre-operative therapy and these patients (non-responders)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Izadi, Fereshteh, Sharpe, Benjamin P., Breininger, Stella P., Secrier, Maria, Gibson, Jane, Walker, Robert C., Rahman, Saqib, Devonshire, Ginny, Lloyd, Megan A., Walters, Zoë S., Fitzgerald, Rebecca C., Rose-Zerilli, Matthew J. J., Underwood, Tim J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308111/ https://www.ncbi.nlm.nih.gov/pubmed/34298611 http://dx.doi.org/10.3390/cancers13143394

Ejemplares similares

The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer
por: Lang, Cameron C. J., et al.
Publicado: (2022)

Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts
por: Sharpe, Benjamin P., et al.
Publicado: (2022)

Histone Modifying Enzymes as Targets for Therapeutic Intervention in Oesophageal Adenocarcinoma
por: Pickering, Oliver J., et al.
Publicado: (2021)

The genetic profile and molecular subtypes of human pseudomyxoma peritonei and appendiceal mucinous neoplasms: a systematic review
por: Murage, Nora Wangari, et al.
Publicado: (2023)

Evidence that polyploidy in esophageal adenocarcinoma originates from mitotic slippage caused by defective chromosome attachments
por: Scott, Stacey J., et al.
Publicado: (2021)

The transcriptional landscape of endogenous retroelements delineates esophageal adenocarcinoma subtypes
por: Kazachenka, Anastasiya, et al.
Publicado: (2023)

Mutational signature dynamics shaping the evolution of oesophageal adenocarcinoma
por: Abbas, Sujath, et al.
Publicado: (2023)

Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics
por: Li, Xiaodun, et al.
Publicado: (2018)

The mutREAD method detects mutational signatures from low quantities of cancer DNA
por: Perner, Juliane, et al.
Publicado: (2020)

The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic
por: Frankell, Alexander M, et al.
Publicado: (2019)

Whole-genome sequencing of nine esophageal adenocarcinoma cell lines
por: Contino, Gianmarco, et al.
Publicado: (2016)

Single-Cell RNA Sequencing Unifies Developmental Programs of Esophageal and Gastric Intestinal Metaplasia
por: Nowicki-Osuch, Karol, et al.
Publicado: (2023)

Author response to: Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery
por: Rahman, Saqib A, et al.
Publicado: (2022)

Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction
por: Bornschein, Jan, et al.
Publicado: (2019)

Alterations in the Ca(2+) toolkit in oesophageal adenocarcinoma
por: Cutliffe, Alana L., et al.
Publicado: (2021)

Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Review of Meta-Analyses
por: Wijnhoven, Bas P. L., et al.
Publicado: (2009)

KCNQ potassium channels modulate Wnt activity in gastro-oesophageal adenocarcinomas
por: Shorthouse, David, et al.
Publicado: (2023)

Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer
por: Noordman, B. J., et al.
Publicado: (2019)

Neoadjuvant and adjuvant therapy in esophageal cancer
por: Weiss, Jennifer A., et al.
Publicado: (2023)

Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer
por: de Heer, E. C., et al.
Publicado: (2017)

Neoadjuvant Therapy for Locally Advanced Esophageal Cancers
por: Huang, Runkai, et al.
Publicado: (2022)

Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients
por: Warnecke-Eberz, Ute, et al.
Publicado: (2020)

Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer
por: Borggreve, Alicia S., et al.
Publicado: (2019)

Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
por: Secrier, Maria, et al.
Publicado: (2016)

Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma
por: Matani, Hirsch, et al.
Publicado: (2022)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer
por: Dings, Mark P.G., et al.
Publicado: (2022)

NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial)
por: van Heijl, Mark, et al.
Publicado: (2008)

ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer
por: Vrana, David, et al.
Publicado: (2018)

Optimal radiation dose in the neoadjuvant management of esophageal cancer
por: Buckstein, Michael
Publicado: (2020)

Neoadjuvant immunotherapy for resectable esophageal cancer: A review
por: Li, Qing, et al.
Publicado: (2022)

Tumor-Infiltrating Neutrophils after Neoadjuvant Therapy are Associated with Poor Prognosis in Esophageal Cancer
por: Cabalag, Carlos S., et al.
Publicado: (2022)

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2022)

Detecting Interval Distant Metastases With (18)F-FDG PET/CT After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer
por: Kroese, Tiuri E., et al.
Publicado: (2022)

Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer
por: Cleary, James M., et al.
Publicado: (2016)

A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy
por: Noorani, Ayesha, et al.
Publicado: (2017)

Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma
por: Goedegebuure, R.S.A., et al.
Publicado: (2021)

Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition
por: van den Ende, Tom, et al.
Publicado: (2023)

Neoadjuvant chemoradiotherapy followed by resection for esophageal cancer: clinical outcomes with the ‘CROSS-regimen’ in daily practice
por: Cloos-v.Balen, Marissa, et al.
Publicado: (2021)

Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy
por: Hulshoff, J. B., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_l9tb5emu255vhkhjvna535dsob